New hope for rare leukemia: targeted combo therapy enters phase 2 trial

NCT ID NCT07224100

First seen Nov 05, 2025 · Last updated May 23, 2026 · Updated 34 times

Summary

This study tests a combination of chemotherapy drugs (DA-EPOCH) plus a targeted pill (ponatinib) in adults newly diagnosed with a fast-growing blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this approach is safe and can wipe out cancer cells at the genetic level. About 33 participants will receive the treatment, and researchers will monitor side effects and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.